Tuberculosis and Pregnancy
Untreated tuberculosis (TB) disease represents a greater hazard to a pregnant woman and her fetus than does its treatment. Treatment of pregnant women should be initiated whenever the probability of TB is moderate to high. Infants born to women with untreated TB may be of lower birth weight than those born to women without TB and, in rare circumstances the infant may be born with TB. Although the drugs used in the initial treatment regimen for TB cross the placenta, they do not appear to have harmful effects on the fetus.
The tuberculin skin test is considered both valid and safe to use throughout pregnancy. The TB blood test is safe to use during pregnancy, but has not been evaluated for diagnosing M. tuberculosis infection in pregnant women. Other tests are needed to show if a person has TB disease.
Latent TB Infection (LTBI) – Isoniazid (INH) administered either daily or twice weekly for 9 months is the standard regimen for the treatment of LTBI in pregnant women. Women taking INH should also take pyridoxine (vitamin B6) supplementation. The 12-dose regimen of INH and Rifapentine (RPT) is not recommended for pregnant women or women expecting to be pregnant within the next 3 months.
TB Disease – Pregnant women should start treatment as soon as TB is suspected. The preferred initial treatment regimen is INH, rifampin (RIF), and ethambutol (EMB) daily for 2 months, followed by INH and RIF daily, or twice weekly for 7 months (for a total of 9 months of treatment). Streptomycin should not be used because it has been shown to have harmful effects on the fetus. In most cases, pyrazinamide (PZA) is not recommended to be used because its effect on the fetus is unknown.
HIV Infection – HIV-infected pregnant women who are suspected of having TB disease should be treated without delay. TB treatment regimens for HIV-infected pregnant women should include a rifamycin. Although the routine use of PZA during pregnancy is not recommended in the United States, the benefits of a TB treatment regimen that includes PZA for HIV-infected pregnant women may outweigh the undetermined potential risks to the fetus.
The following antituberculosis drugs are contraindicated in pregnant women:
Women who are being treated for drug-resistant TB should receive counseling concerning the risk to the fetus because of the known and unknown risks of second-line antituberculosis drugs.
Breastfeeding should not be discouraged for women being treated with the first-line antituberculosis drugs because the concentrations of these drugs in breast milk are too small to produce toxicity in the nursing newborn. For the same reason, drugs in breast milk are not an effective treatment for TB disease or LTBI in a nursing infant. Breastfeeding women taking INH should also take pyridoxine (vitamin B6) supplementation.
For More Information
- CDC. Treatment of tuberculosis.MMWR 2003; 52 (No. RR–11).
- American Thoracic Society/CDC. Targeted tuberculin testing and treatment of latent TB infection.. (PDF) MMWR 2000: 49(No. RR–6).
- CDC. Guidelines for using the QuantiFERON®-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. (PDF) MMWR 2005; 54 (No. RR-15).
- CDC. Recommendations for Use of an Isoniazid–Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection. MMWR 2011;60:1650–1653.
- Targeted Tuberculosis (TB) Testing and Treatment of Latent TB Infection (Slide Set)